Category Archives: Emerging Markets

A Glimpse of Health in 2030: Global Trends

By Clark Herman | Published: December 13, 2012
The National Intelligence Council’s Global Trends Report explains the scenarios in which the next 18 years may play out internationally. Some of the predictions addressed matters of global health and health technologies playing a role in the future of medicine.
Also posted in Global, R&D, Strategy, Technology, healthcare | Leave a comment

Pharma's Reputation: A Boost in the US, but China Strikes a Sour Note

By Clark Herman | Published: November 30, 2012
The pharmaceutical industry’s global reputation is on the mend, even if some countries – notably China – are more hostile, according to the latest Ipsos Reputation Snapshot for the Pharmaceutical Sector, from the Ipsos Global Reputation Centre. Since the last Ipsos survey in 2008, pharma’s reputation has improved significantly in the US, more so than in [...]
Also posted in Corporate Responsibility, Safety, Strategy | Tagged | Leave a comment

Pharma Forecast 2020: Cold Comfort

By Clark Herman | Published: November 16, 2012
Price Waterhouse Cooper’s “Pharma 2020: From vision to decision” parses a mix of gloomy and glowing scenarios that reflect the fickle, delicate nature of today’s industry. On the one hand, innovations in other areas such as mobile technology promise to breathe new life into pharma with cutting-edge initiatives. On the opposite end, stark fiscal realities [...]
Also posted in Europe, FDA, Global, IP, R&D, Regulatory, Strategy, compliance, pricing | Leave a comment

IP Climate Change: Patent Rights Face Headwinds

By Clark Herman | Published: November 6, 2012
The pharmaceutical industry as of late has faced a growing movement against patent protection in favor of providing access to low cost medicines, specifically in developing countries. In Indonesia, the government imposed compulsory licensing on seven drugs used to treat HIV and Hepatitis B in September. In July, China passed a law which grants it power [...]
Also posted in IP, Legal, Market Access, Regulatory, pricing | 1 Comment

SciClone Pharmaceuticals: Selling Specialty Drugs in China

By Ben Comer | Published: October 1, 2012
US-based SciClone Pharmaceuticals has built its business around selling specialty drugs in China. Companies like Sanofi and Pfizer, despite their own in-country resources, have partnered with SciClone and are achieving better returns, according to SciClone CEO Friedhelm Blobel.
Also posted in Biotech, Global, IP, Legal, Manufacturing, People, Regulatory, Sales, Strategy, compliance, healthcare, pricing | Tagged , , | 1 Comment